398 POSTER Phase I, pharmacokinetic (PK), dose-escalation study of EZN-2968, a novel hypoxia-inducible factor-1 alpha (HIF-1a) antagonist, administered weekly in patients (pts) with solid tumours
2008 ◽
Vol 6
(12)
◽
pp. 125
◽
Keyword(s):
Phase I
◽